Startsida2269 • HKG
add
WuXi Biologics (Cayman) Inc
Föregående stängning
15,50 $
Dygnsintervall
15,56 $ - 16,76 $
Årsintervall
10,14 $ - 38,00 $
Börsvärde
69,47 md HKD
Genomsnittlig volym
50,76 mn
P/E-tal
25,56
Direktavkastning
-
Primär börs
HKG
Ekonominyheter
Ekonomi
Resultaträkning
Intäkter
Nettoinkomst
| (CNY) | juni 2024info | Förändring Y/Y |
|---|---|---|
Intäkter | 4,29 md | 0,97 % |
Rörliga kostnader | 765,14 mn | 21,62 % |
Nettoinkomst | 749,54 mn | −33,86 % |
Nettovinstmarginal | 17,48 | −34,51 % |
Vinst per aktie | — | — |
EBITDA | 1,24 md | −13,32 % |
Giltig skattesats | 11,36 % | — |
Balansräkning
Totala tillgångar
Totala ansvarsskyldigheter
| (CNY) | juni 2024info | Förändring Y/Y |
|---|---|---|
Kontanta och kortsiktiga investeringar | 9,53 md | 9,60 % |
Totala tillgångar | 56,11 md | 7,60 % |
Totala ansvarsskyldigheter | 11,46 md | −12,46 % |
Totala tillgångar | 44,64 md | — |
Utestående aktier | 4,15 md | — |
P/B | 1,58 | — |
Avkastning på tillgångar | 4,05 % | — |
Avkastning på kapital | 4,62 % | — |
Kassaflöde
Förändring i nettokassa
| (CNY) | juni 2024info | Förändring Y/Y |
|---|---|---|
Nettoinkomst | 749,54 mn | −33,86 % |
Kontanter från verksamhet | 651,06 mn | −52,65 % |
Kontanter från investering | −191,26 mn | 75,93 % |
Kontanter från finansiering | −737,79 mn | −684,70 % |
Förändring i nettokassa | −258,16 mn | −153,79 % |
Fritt kassaflöde | 350,65 mn | 52,56 % |
Om
WuXi Biologics is a global Contract Research Development and Manufacturing Organization that provides open-access, integrated technology platforms for biologics drug development.
WuXi Biologics' roots date back to 2010, and began building out capabilities and facilities required for biologics discovery, development and GMP manufacturing. WuXi Biologics went public on the Hong Kong Stock Exchange in June 2017.
As of 2021, WuXi Biologics has 18 manufacturing sites including ten in China, three in the United States, two in Ireland, two in Germany, and one in Singapore.
In August 2020, WuXi Biologics was selected to become a component of the Hang Seng Index in Hong Kong.
In January 2024, WuXi Biologics' share price fell on news that the United States Congress had introduced legislation to block any federal government contracts with the company due to national security concerns. The concerns stem from allegations, denied by the company, that it has worked closely with the People's Liberation Army as a part of the Chinese Communist Party's military-civil fusion strategy. Wikipedia
Grundades
2010
Hemsida
Anställda
12 435
